Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

Urothelial Carcinoma Ureter Clinical Trial

Official title:
Preventing Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract: a Pilot Randomized Trial of a Single Prophylactic Bladder Instillation of Mitomycin C After Diagnostic Ureteroscopy

Status Not yet recruiting

Clinical Trial Summary

The objective of this pilot study is to determine the feasibility of conducting a phase III randomized trial of intravesical mitomycin C (MMC) for prevention of intravesical recurrence (IVR) after diagnostic ureteroscopy for suspected upper tract urothelial carcinoma (UTUC). In the current study, 40 patients will be randomized to receive MMC or no intervention and will be followed for two years to determine the incidence of adverse events and IVR.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05979909
Study type	Interventional
Source	McMaster University
Contact	Piotr Zareba, MD MPH
Phone	(905) 521-2100
Email	zareba@hhsc.ca
Status	Not yet recruiting
Phase	Phase 1
Start date	September 2023
Completion date	September 2027

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03606174` - A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma	Phase 2
Recruiting	`NCT04865939` - Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma	Phase 3
Recruiting	`NCT05874921` - uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Recruiting	`NCT06120387` - Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Available	`NCT05494411` - Named Patient Program for Mitomycin for Pyelocalyceal Solution